Sign up
Pharma Capital

Orthocell's European regulatory approval may be on the horizon

The halt will remain in place until Friday 10th November 2017.
Orthocell's European regulatory approval may be on the horizon
The company's shares are in pre-open

Orthocell Ltd (ASX:OCC) has been granted a trading halt by the ASX this morning, pending details in relation to its application for European regulatory approval (CE Mark) of its CelGro® collagen medical device.

CelGro® is a collagen medical device platform for soft tissue regeneration and repair applications.

The CE Mark would provide commercialisation opportunities.

The halt will remain in place until the opening of trade on Friday 10th November 2017, or earlier if an announcement is made to the market.



Register here to be notified of future OCC Company articles
View full OCC profile

Orthocell Ltd Timeline

Newswire

Orthocell gets ready to raise

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.